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Abstract Objective: We investigated
the metabolic, hemodynamic, and
inflammatory responses of pharma-
cological and physical therapies
aimed at reducing body temperature
in febrile critically ill patients. De-
sign and setting: Open-label, ran-
domized trial in a surgical ICU in a
tertiary university hospital. Patients:
Thirty analgosedated, mechanically
ventilated patients with a temperature
of 38.5C or higher were randomized
to receive either intravenous
metamizol, intravenous propaceta-
mol, or external cooling. Measure-
ments and results: Body temperature
and metabolic and hemodynamic
variables were recorded at baseline
and during the following 4 h. Cyto-
kine concentrations were assessed
before and 4 and 12 h after the
initiation of antipyresis. Body tem-
perature decreased significantly in all
treatment groups. For a 1C temper-
ature decrease, the energy expendi-
ture index increased by 5% with
external cooling and decreased by 7%
and 8% in the metamizol and
propacetamol groups, respectively.
Metamizol induced a significant de-
crease in mean arterial pressure and
urine output compared to baseline
and to the other two groups. C-
reactive protein increased over time,
but compared to the other groups it
was significantly lower in patients
receiving metamizol after 4 h. Cyto-
kine concentrations were not differ-
ent among the three groups or over
time, although interleukin 6 tended to
decrease over time in the metamizol
group. Conclusions: Metamizol,
propacetamol, and external cooling
equally reduced temperature. Con-
sidering the undesirable hemody-
namic effects, metamizol should not
be considered the first antipyretic
choice in unstable patients. Propac-
etamol or external cooling should be
preferred, although the latter should
be avoided in patients unlikely to
tolerate the increased metabolic de-
mand induced by external cooling.
Keywords Adult · Cytokines ·
Fever · Human · Intensive care unit ·
Temperature
Introduction
Fever is a common sign in critically ill patients, related
either to systemic inflammatory response syndrome
(SIRS) or infection. Although the controversy on the
value of treating fever is not settled, when body
temperature rises above 38.5C, an antipyretic therapy
is usually initiated. The treatment options consist of
administering drugs such as paracetamol or metamizol
and/or applying of external cooling. Arguments advanced
in support of reducing fever are the reduction in patient’s
metabolic demand and the resulting myocardial or
cerebral oxygen consumption, and improvement in
patient comfort. The deleterious hemodynamic and met-
abolic consequences of fever are particularly undesirable
if a preexisting cardiac disease is present or during sepsis
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where the myocardial function is depressed [1] or in the
acute phase of cerebral damage. Furthermore, since these
treatments reduce fever through different pathways [2, 3,
4], their effect on the concentration of plasma inflamma-
tory markers is expected to be different, and this has not
been extensively investigated.
In a previous crossover study we demonstrated that
antipyresis by physical means is more effective in
reducing body temperature than metamizol or propaceta-
mol, and that a significant decrease in energy expenditure
(EE) accompanies the defervescence, probably because
sedation blunted the shivering mechanism [5]. However,
the lack of randomization, possibly incomplete drug
wash-out due to the crossover design, and an antipyretic
dose not adjusted for body weight limited the interpre-
tation of the study. Therefore a randomized, prospective,
open-label study was designed to investigate the respec-
tive effects of centrally acting drugs (propacetamol and
metamizol) or external cooling in febrile critically ill




The ethics committee at our institution approved the study. The
patient or the next of kin gave informed consent. Inclusion criteria
included: age older than 18 years, a Simplified Acute Physiology
Score II (SAPS II) greater than 30, and a rectal or core (pulmonary
artery) temperature greater than 38.5C for at least 1 h, accompa-
nied by at least two SIRS criteria [6]. Additionally, the lungs had to
be mechanically ventilated and the patients hemodynamically
stable for at least 6 h prior to randomization. Exclusion criteria
included: renal insufficiency (defined as a creatinine clearance of
<50 ml/min), liver dysfunction (defined as the presence of hepatic
cirrhosis, and/or a concentration of serum transaminases and
bilirubin of greater than twice the upper limit of the normal range),
leukopenia, known allergy to metamizol and/or paracetamol,
inspired oxygen fraction (FIO2) greater than 0.6, pneumothorax,
bronchopleural fistula, acute neurological disease, and immunode-
ficiency or immunosuppressive regimens. Patients were also
excluded if propacetamol, paracetamol, or metamizol had been
administered between 6 and 16 h prior to randomization. Thirty
patients admitted met the inclusion criteria; all tolerated the
protocol well and were included in the analyses. Demographic data
and admission diagnoses are shown in Tables 1 and 2.
Computer generated three-unit block randomization was used
for treatment allocation. Patients were randomized to receive an
intravenous bolus of metamizol (16 mg/kg body weight, maximum
of 2 g) or propacetamol (30 mg/kg body weight, maximum of 2 g)
or external cooling by a cooling blanket (Bair hugger, Augustine
Medical, Eden Prairie, Minn., USA) and by cloths plunged into iced
water and by ice packs applied on most of the body surface. The
three treatment groups were similar in baseline characteristics. The
level of sedation was similar across groups during the study period;
the median (interquartile range) Ramsay score was 5.5 (4.25–6)
with metamizol, 5 (4.25–5.75) with propacetamol, and 5 (4–6) with
external cooling.
Prior to the beginning of the study analgesia and sedation were
adjusted by a continuous infusion of morphine ( 1 mg/h) and
midazolam ( 1 mg/h) to obtain a Ramsay sedation score of 4 or
higher [7]. Ventilatory settings, adjusted to obtain arterial blood-gas
tensions in a normal range, were remained constant during the
study. Patients were kept supine during the study and nursing
intervention was minimized as much as possible. EE was measured
Table 1 Demographic charac-
teristics of randomized patients,
by assigned treatment (SAPS II
Simplified Acute Physiology
Score II)
Metamizol (n=10) Propacetamol (n=10) External cooling (n=10)
Age (years) 54€25 55€14 53€15
Sex: M/F 9/1 9/1 7/3
SAPS II 53€15 51€17 46€12
Ramsay score 5.1€1.1 4.8€1.2 4.8€1.2
Midazolam rate (mg/h)a 0.7€0.5 1.4€1.3 2.8€3.0
Midazolam/24 h 17.5€11.4 24.6€37.8 50.3€65.3
Morphine rate (mg/h)a 1.0€0.7 1.3€1.4 2.5€2.9
Morphine/24 h 21.9€17.5 27.4€36.6 48.9€81.3
Nutrition: yes/no 3/7 4/6 3/7
kcal/24 hb 763€456 1268€970 1497€669
Antibiotic use: yes/no 6/4 6/4 5/5
ICU mortality (%) 50 40 30
a During the study period
b Among patients receiving nutrition
Table 2 Distribution of inten-
sive care unit admission diag-








Acute respiratory distress syndrome 1 0 1
Ischemic heart disease 0 2 1
Multiple trauma 2 2 2
Pancreatitis 1 0 1
Pneumonia 3 2 1
Sepsis or septic shock 3 4 3
Upper gastrointestinal bleeding 0 0 1
403
by indirect calorimetry at baseline to ensure that no patient had a
caloric intake higher than required and was standardized by body
surface area (energy expenditure index, EEI).
Study protocol
After randomization hemodynamic and calorimetric variables were
recorded. Prior to the initiation of either metamizol, propacetamol,
or external cooling a steady state was established, defined as less
than 10% change in both hemodynamic and calorimetric data for at
least 30 min. All variables were then measured hourly over a 4-h
period [t0 (prerandomization baseline), t1, t2, t3, t4). In the external
cooling group wet cloths were changed every 30 min to optimize
the cooling treatment. Based on the pharmacokinetic properties of
both antipyretic drugs administered, the primary study end-point
was defined as the defervescence induced 4 h after the initiation of
the intervention.
Core temperature was measured by a thermistor-tipped pulmo-
nary artery catheter and/or rectal temperature by digital electronic
thermometer. Skin temperature was measured on the upper thoracic
body surface area by a thermistor-tipped thermometer (Elctron-
ique, G. Mtraux, Crissier, Switzerland). Indirect calorimetry was
performed using a Deltatrac II MBM-100 apparatus (Datex
Instrumentarium, Helsinki, Finland). Before the patient’s connec-
tion the Deltatrac II was calibrated for room air, atmospheric
pressure, and a standard gas blend containing 95% oxygen and 5%
carbon dioxide according to the manufacturer’s instructions. CO2
production (V˙CO2) is calculated as the product of the CO2 fraction
in the diluted expiratory flow and a constant flow of 45 l/min.
Oxygen consumption (V˙O2) is calculated as V˙CO2 divided by the
respiratory quotient (RQ), where: RQ=1FiO2/[(FiO2FE0 O2)/
FE0 CO2]FiO2.
Data measurements
Data collected consisted of rectal or core and skin temperatures,
heart rate, mean arterial pressure, respiratory rate, expired minute
ventilation, arterial pH, PaCO2, PaO2, HCO3, lactate, V¯O2, V¯CO2,
EEI, RQ, and urine output. When a pulmonary artery catheter was
in place (n=25), mean pulmonary artery pressure, pulmonary artery
wedge pressure, cardiac output, and central venous pressure were
also recorded. Arterial blood gas analyses were performed by Stat
profile (Nova Biomedical, Boston, Mass., USA). Urine samples
were collected hourly and stored at 8C for vanilmandelic acid
concentration. Urine samples were processed after the addition of
an internal standard by absorption on an anion-exchange column to
retain organic acids. Vanilmandelic acid and the internal standard
were then eluted and determined by high-performance liquid
chromatography with electrochemical detection. Separation was
achieved on a reversed-phase column and the detection by
electrochemistry in amperometric mode. Quantitation used an
internal standard method. Analytical reproducibility for vanilman-
delic acid was 7%. Arterial blood samples for analysis of C-reactive
protein (CRP), interleukin (IL) 1Ra, IL-6, IL-8, tumor necrosis
factor (TNF) a, and TNF-sR75 were taken at baseline and 4 h and
12 h after initiation of treatment. CRP was measured using a
nephelometric assay (Immage Beckman). The sensitivity of the
assay is 0.4 mg/l. The normal range in human serum is less than
4 mg/l. The sensitivity, normal range in human serum, and intra-
and interassay coefficients of variation for cytokines are shown in
Table 3. IL-6, IL-8, IL-1Ra, TNFa, and TNF-sR75 were measured
using commercially available quantitative sandwich enzyme im-
munoassays (Quantikine human, R&D, UK). Serum samples were
assayed at one-fourth dilution. For all the immunoassays the
coefficient of variation is less than 7% for intra-assay and 10% for
interassay.
Statistical analysis
The study was designed to detect a defervescence from baseline of
1C with a standard deviation of 0.6C based on data from our
previous study. Accordingly, the sample size was ten patients per
treatment group with a probability of a type I error of 0.05 (two-
tailed) and a b power of 0.95. Initial exploratory data analysis was
conducted to determine the distribution of the baseline character-
istics, balance of the randomization process, completeness of data
collection, and longitudinal pattern of the observations. At each
observation time a cross-sectional analysis of the treatment effect
on temperature, metabolism, hemodynamics, and cytokines was
performed using analysis of covariance, adjusting for baseline
values to increase precision. Cytokine values were log transformed
for model building. Generalized estimating equations [8] were used
to evaluate the longitudinal effect of treatment on defervescence,
metabolism, hemodynamics, and cytokines. All models included
treatment as the main predictor and adjusted for baseline values.
The level of significance was set at 5%. Statistical analyses were
run using the statistical package STATA (Stata version, 7.0, Tex.,
USA). Results are reported as means (95% confidence intervals).
Results
General characteristics
Body temperature and metabolism changes
In all treatment groups temperature began to fall signif-
icantly 2 h after the beginning of treatment (Fig. 1a), and
after 4 h the average defervescence was similar between
the three groups: 0.9C, 0.5C, and 0.6C (95% confi-
dence intervals: 0.5 to 1.2, 0.2 to 0.8, 0.4 to 0.8C) for
metamizol, propacetamol, and external cooling, respec-
tively. In addition, external cooling significantly reduced
skin temperature from 35.1€0.9C to 33.8€1.4C
(p=0.004) 4 h after the start of the treatment. There were
no differences in temperature between the three groups at
Table 3 Sensitivity, normal
range in human serum, intra-
and inter-assay coefficient of
variation for cytokine measure-
ments
Cytokine Sensitivity Normal range
in human serum
Coefficient of variation (%)
Intra-assay Inter-assay
IL-6 0.7 pg/ml <15 pg/ml <5 4
IL-8 10 pg/ml <32 pg/ml <7 10
IL-1Ra 14 pg/ml 106–1552 pg/ml <7 7
TNFa 4.4 pg/ml <15.6 pg/ml <6 8
TNF-sR75 10 pg/ml 1.0–3.2 ng/ml <3 6
404
any time point during the entire study period either in the
cross-sectional or the longitudinal analyses.
Metabolic variables are shown in Table 4 and Fig. 1b.
Adjusting for baseline, there was a significant difference
at 4 h in mean EEI between the propacetamol and
metamizol groups vs. the external cooling group. The
mean daily EEI was 125.5 kcal/m2 (243.1 to 7.9,
p=0.037) lower with propacetamol and 151.3 kcal/m2
(270.5 to 32.0, p=0.015) lower with metamizol than in
the external cooling group. Also, V˙O2 was different
between the groups after 4 h, being significantly lower in
the propacetamol group (44.53 ml/min, 82.17 to 6.90,
p=0.022) and metamizol group (45.11 ml/min, 83.47 to
6.75, p=0.023) than the external cooling group. Simi-
larly, over the entire study period the effect of external
cooling on V˙O2 differed significantly from that in the
other two treatments: compared with external cooling
there was a mean V˙O2 difference of 22.4 ml/min (43.5
to 1.26) with propacetamol and one of 25.7 ml/min
(49.2 to 2.18) with metamizol for every hour elapsed.
The difference in daily EEI between external cooling and
propacetamol was 65.7 kcal/m2 (149.2 to 17.8) and that
between external cooling and metamizol was 102.2 kcal/
m2 (173.4 to 30.9). During the study period there was a
nonsignificant increase in EEI and V˙O2 by 5% (3% to
13%, p=0.188) and 13% (1% to 28%, p=0.06) respec-
tively, per 1C of temperature reduction in the external
cooling group, while EEI decreased by 7% (4% to 10%,
p<0.01) per 1C of temperature reduction in the metami-
zol and by 8% (3% to 12%, p<0.01) per 1C of
temperature reduction in the propacetamol group.
Table 4 Metabolic and hemodynamic variables at baseline and 4 h after the initiation of antipyresis (t4), by assigned treatment
Metamizol (n=10) Propacetamol (n=10) External cooling (n=10)
Baseline t4 Baseline t4 Baseline t4
Core temperature (C) 39.1€5 38.2€** 38.7€3 38.2€6* 39.0€5 38.4€7*
CO2 production (ml/min) 250€41 232€44** 228€41 219€43 239€61 252€97
O2 consumption (ml/min) 304€57 290€60 263€38 259€40 283€77 315€96
Energy expenditure index (kcal/m2 daily) 1052€151 994€169 1012€124 984€140 992€166 1091€231
Heart rate (beats/min) 104€28 100€28 112€17 110€25 118€32 112€32
Stroke volume (ml; n=8) 74€39 75€35 57€17 62€20 70€35 69€29
Mean arterial pressure (mmHg) 71€16 70€10 70€11 72€13 73€12 78€12*
Pulmonary artery wedge pressure (mmHg; n=8) 17€6 17€8 13€3 14€4 16€8 15€5
Urine output (ml/h) 55€42 25€19* 44€52 47€45 76€56 69€52
*p<0.05, **p<0.01, baseline vs. t4
Fig. 1 Time course of mean
body temperature (a), energy
expenditure index (b), mean
arterial pressure (c) and urinary
vanilmandelic acid concentra-
tion (d) in patients randomized
to receive metamizol, propac-
etamol, and external cooling.
Bars Standard errors. Cross-
sectional comparison between
treatment groups: † p<0.05,
‡ p<0.01, metamizol vs. exter-
nal cooling, *p<0.05 propac-
etamol vs. external cooling
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The PaO2/FIO2 ratio did not change significantly, but
respiratory rate and expired minute ventilation fell
significantly during the study in the metamizol group.
No significant changes and differences between the
treatment groups were found for pH, PaO2, PaCO2,
HCO3-, or serum lactate concentration.
Hemodynamic changes
Systemic and pulmonary hemodynamic variables are
shown in Table 4. Mean arterial pressure decreased from
71€16 mmHg at baseline to 62€13 mmHg at t2 after the
administration of metamizol (p=0.008) and then returned
to baseline values at t4. Mean arterial pressure was
significantly lower in the metamizol group than the
external cooling group at all the time points after baseline
(Fig. 1c). The longitudinal effect of external cooling on
blood pressure differed significantly from that of the other
two treatments: compared with external cooling there was
a mean difference of 4.8 mmHg (7.8 to 1.8) with
propacetamol and 7.8 mmHg (11.45 to 4.07) with
metamizol. Concomitant with the reduction in blood
pressure there was a decrease from baseline in urine
output at t3 and t4 (Table 4; p=0.012) in the metamizol
group. The difference was significant compared with that
in the external cooling group at t3 and t4 (overall mean
difference: 16.8 ml/h, 33.4 to 28.0). No changes in
cardiac output, mean pulmonary artery, mean pulmonary
artery wedge, or central venous pressures were observed
during the study period.
Biological assay
Overall CRP increased after 12 h in all groups by a mean
of 28.7€12.5 mg/l (p=0.033). Compared with the external
cooling group CRP was significantly lower at t4 in the
propacetamol group (39.45 mg/l, 66.75 to 12.15,
p=0.007) after adjusting for baseline values. The group
receiving metamizol did not differ from the external
cooling group. IL-6, IL-8, and IL-1ra were highly
elevated at baseline compared to normal concentrations
(Table 5). Overall the log IL-6 decreased by
0.402€1.15 pg/ml after 4 h compared to baseline
(p=0.017). At t4 and t12 the decrease in log IL-6 was
marginally significant in the metamizol group compared
to baseline (p=0.08 and p=0.04, respectively). However,
there were no significant differences among the three
groups. No patterns over time or differences across the
groups were found for IL-8 and IL-1Ra. TNFa was only
slightly increased in a few patients and remained within
the normal range for most patients. TNF-sR75, which
prevents the binding of TNFa to its membrane receptor,
was also only slightly elevated, without changes upon
treatment. Similarly, no significant changes between the
treatment groups were observed in urine concentrations of
vanilmandelic acid (Fig. 1d). Consistent with this, in all
treatment groups SIRS was still present in a comparable
number of patients 12 h after start of antipyresis (9 of 10,
10 of 10, and 8 of 10 with metamizol, propacetamol, and
external cooling, respectively).
Discussion
The present findings show that pharmacological and
physical means are equally effective in reducing temper-
ature. Metamizol and propacetamol, but not external
cooling, reduced EE and oxygen consumption by 5–7%
for every 1C decrease in temperature. After 4 h EE was
significantly higher in the external cooling group than the
other two groups. However, metamizol significantly
decreased blood pressure and urine output, while mean
arterial pressure was unchanged with propacetamol, and
increased with external cooling. During defervescence
there was an overall increase in CRP, but this increase
was blunted after 4 h in patients receiving metamizol. No
patterns over time or important differences across the
groups were found for other cytokines.
In agreement with the physiological response to a cold
stress, which normally consists in heat conservation and
heat production, external cooling increased EE in the
patients studied despite the decrease in body temperature.
In contrast with this observation, previous studies report-
ed that external cooling decreases EE, possibly because
Table 5 Biological assay variables at baseline and 12 h after the initiation of antipyresis (t12), by assigned treatment
Metamizol (n=10) Propacetamol (n=10) External cooling (n=10)
Baseline t12 Baseline t12 Baseline t12
CRP (mg/l) 267€74 285€88 207€91 248€124* 233€70 271€95*
IL-1Ra (ng/ml) 46.5€61.5 61.5€14.2 35.4€59.0 15.6€19.0 22.3€24.3 13.8€17.3*
IL-6 (ng/ml) 4.2€9.7 1.0€1.6* 10.5€29.7 4.3€11.9 2.4€3.7 2.4€4.1
IL-8 (ng/ml) 0.19€35 0.10€0.01 0.61€1.48 0.26€0.50 0.40€0.69 0.13€0.20
TNFa (pg/ml) 15.2€0.7 15€0 18.0€7.6 15€0 17.0€5.6 15.7€1.9
TNF-sR75 (ng/ml) 6.0€3.1 6.1€2.4 5.6€3.8 5.3€3.3 5.4€3.3 4.8€1.9
*p<0.05, baseline vs. t12
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shivering was suppressed by sedation or therapeutic
paralysis [5, 9]. However, in our externally cooled patient
group EE increased despite clinically adequate sedation
and the absence of a visible shivering response, suggest-
ing that the increase in EE by external cooling involves
other mechanisms than shivering which are not entirely
blunted by sedation. The reason for the decrease in EE
with external cooling in the above studies could be
treatment crossover and/or the prior administration of
antipyretic drugs, causing the hypothalamic thermostat to
reset at a normal level. Therefore the body may have
reacted with heat loosing mechanisms rather than heat
production, thus exhibiting a decrease in EE. We
specifically addressed this point when we designed the
study. Indeed, no treatment crossover was allowed, and
only patients free of prior antipyretic agents were
enrolled.
In the present study the lack of a role of shivering in
increasing EE is further supported by the absence of
concomitant increased catecholamine secretion. However,
shivering cannot definitively be discarded given the lack
of neuromuscular blockade in our patients, even though
no clinical signs of mild shivering were detected, and
electrocardiographic recordings did not suggest back-
ground noise in the tracing. Other possible mechanisms of
nonshivering thermogenesis through brown adipose tissue
would be very unlikely in adults [10, 11]. In patients
treated with metamizol or propacetamol we found a 5–7%
decrease in EE per 1C of defervescence. This observa-
tion is consistent with recent data reporting a 6–10%
change in metabolism per 1C change in body temper-
ature [5, 9, 12, 13] and contrasts with an earlier study
showing more important changes in metabolism in the
order of 13% per 1C of change in body temperature [14].
The latter study may have suffered from less sophisticated
metabolic measurement techniques and referred to nor-
mal, conscious individuals. On the other hand, the change
in metabolic rate may be not linear over different ranges
of temperature.
Few studies have evaluated the cardiovascular re-
sponse to antipyresis in the critically ill febrile patient.
Previous investigations observed that the resolution of
fever without antipyretic treatment increased the left
ventricular stroke volume index and concluded that the
left ventricular performance is enhanced as a result of
defervescence [1, 15]. Although effective as antipyretic
agent, metamizol induced undesirable hemodynamic
effects. Indeed, metamizol infusion reduced mean arterial
pressure by about 10 mmHg and required an increase in
vasoactive doses in all treated patients. Metamizol-
induced hypotension has previously been reported in a
retrospective study describing severe hypotensive epi-
sodes every 300 patients receiving parenteral administra-
tion [16, 17]. The incidence of hypotension was much
higher in the present study and was observed exclusively
in patients requiring hemodynamic support. The hypo-
tension may be caused by peripheral vasodilatation due to
the known smooth-muscle cell relaxing effect of metami-
zol and/or by a not yet described negative inotropic
property of the drug. These hemodynamic effects are
probably not innocuous because some degree of reper-
cussion on tissue perfusion was probably present after
metamizol infusion. Indeed, the fall in urine output could
reflect such decreased renal perfusion. Inhibition of the
prostaglandin synthesis, which may lead to the retention
of sodium and water and to a decrease in glomerular
filtration may have also occurred and account for the fall
in urine output.
The inflammatory response was not influenced by the
three antipyretic treatments, as seen by the lack of
significant changes between the treatment groups in
serum cytokine concentrations. However, metamizol
seemed to have a short-lived effect (within 4 h) in
reducing CRP and IL-6. Consistent with this, in all
treatment groups SIRS was clinically persisting in almost
all patients 12 h after the start of antipyresis. The
endogenous mediators of fever IL-6 and IL-8 are
markedly elevated in patients when fever reaches
38.5C and this is in agreement with other studies [18,
19, 20]. Moreover, circulating levels of IL-6 are known to
have the highest correlation with changes in body
temperature [19, 20], and in our patients IL-6 and IL-8
concentrations tended to decrease upon treatment. This
effect was noted only in the group receiving metamizol.
Therefore the mechanism of this decrease remains unclear
because prostaglandin E2 is involved in fever induced by
IL-6 [21] but not in that induced by IL-8, and the same
effect should have been observed with propacetamol via
the inhibition of prostaglandin E2. IL-1Ra, as with IL-1,
is induced by inflammatory stimuli and prevents the
action of IL-1 if it reaches a molar ratio greater than
500:1. In animal models IL-1Ra limits the duration rather
than the magnitude of fever [22]. IL-1 concentrations,
which are rarely detectable at the systemic level, were not
measured, but we observed high concentrations of
circulating IL-1Ra, which were not effective in prevent-
ing induction of fever in our patients. It is likely that in
these patients IL-1Ra rather reflects the inflammatory
response, IL-1Ra being a very sensitive acute-phase
protein [23].
Antipyretic therapy is often prescribed in clinical
practice when body temperature reaches 38.5C and is
considered to have failed if no clinically relevant effect is
observed within 2 h after the administration. However, the
present study points out that curtailing the time required
for the drug to be effective is presumably inappropriate.
Indeed, if correct doses adapted to body weight are
applied (16 mg/kg body weight for metamizol, 30 mg/kg
body weight for propacetamol) the peak antipyretic action
is expected to be 3–4 h after administration. Therefore
only after this period should other antipyretic treatments
be considered, if no effect is noted.
407
References
1. Haupt MT, Rackow EC (1983) Adverse
effects of febrile state on cardiac per-
formance. Am Heart J 105:763–768
2. Shimada SG, Otterness IG, Stitt JT
(1994) A study of the mechanism of
action of the mild analgesic dipyrone.
Agents Actions 41:188–192
3. Boutaud O, Aronoff DM, Richardson
JH, Marnett LJ, Oates JA (2002) De-
terminants of the cellular specificity of
acetaminophen as an inhibitor of pros-
taglandin H (2) synthases. Proc Natl
Acad Sci U S A 99:7130–7135
4. Coimbra C, Boris-Moller F, Drake M,
Wieloch T (1996) Diminished neuronal
damage in the rat brain by late treat-
ment with the antipyretic drug dipyrone
or cooling following cerebral ischemia.
Acta Neuropathol (Berl) 92:447–453
5. Poblete B, Romand JA, Pichard C,
Konig P, Suter PM (1997) Metabolic
effects of i.v. propacetamol, metamizol
or external cooling in critically ill
febrile sedated patients. Br J Anaesth
78:123–127
6. Bone RC, Balk RA, Cerra FB, Dellinger
RP, Fein AM, Knaus WA, Schein RM,
Sibbald WJ (1992) Definitions for sep-
sis and organ failure and guidelines for
the use of innovative therapies in sepsis.
The ACCP/SCCM Consensus Confer-
ence Committee. American College of
Chest Physicians/Society of Critical
Care Medicine. Chest 101:1644–1655
7. Ramsay MA, Savege TM, Simpson BR,
Goodwin R (1974) Controlled sedation
with alphaxalone-alphadolone. BMJ
2:656–659
8. Burton P, Gurrin L, Sly P (1998)
Extending the simple linear regression
model to account for correlated re-
sponses: an introduction to generalized
estimating equations and multi-level
mixed modelling. Stat Med 17:1261–
1291
9. Manthous CA, Hall JB, Olson D, Singh
M, Chatila W, Pohlman A, Kushner R,
Schmidt GA, Wood LD (1995) Effect
of cooling on oxygen consumption in
febrile critically ill patients. Am J
Respir Crit Care Med 151:10–14
10. Astrup A, Bulow J, Christensen NJ,
Madsen J (1984) Ephedrine-induced
thermogenesis in man: no role for
interscapular brown adipose tissue. Clin
Sci (Colch) 66:179–186
11. Plattner O, Semsroth M, Sessler DI,
Papousek A, Klasen C, Wagner O
(1997) Lack of nonshivering thermo-
genesis in infants anesthetized with
fentanyl and propofol. Anesthesiology
86:772–777
12. Bruder N, Raynal M, Pellissier D,
Courtinat C, Francois G (1998) Influ-
ence of body temperature, with or
without sedation, on energy expenditure
in severe head-injured patients. Crit
Care Med 26:568–572
13. Stettler N, Schutz Y, Whitehead R,
Jequier E (1992) Effect of malaria and
fever on energy metabolism in Gambian
children. Pediatr Res 31:102–106
14. DuBois E (1954) Energy metabolism.
Annu Rev Physiol 16:125–134
15. Pesenti A, Riboni A, Basilico E, Grossi
E (1986) Antipyretic therapy in ICU
patients: evaluation of low dose diclo-
fenac sodium. Intensive Care Med
12:370–373
16. Zoppi M, Hoigne R, Keller MF, Streit
F, Hess T (1983) [Reducing blood
pressure with Dipyron (novaminsulfone
sodium)]. Schweiz Med Wochenschr
113:1768–1770
17. Hoigne R, Zoppi M, Sollberger J, Hess
T, Fritschy D (1986) Fall in systolic
blood pressure due to metamizol (di-
pyrone, noramidopyrine, novaminsul-
fone). Results from the Comprehensive
Hospital Drug Monitoring Berne
(CHDMB). Agents Actions Suppl
19:189–195
18. Jansky L, Vybiral S, Pospisilova D,
Roth J, Dornand J, Zeisberger E,
Kaminkova J (1995) Production of
systemic and hypothalamic cytokines
during the early phase of endotoxin
fever. Neuroendocrinology 62:55–61
19. Roth J, Conn CA, Kluger MJ, Zeis-
berger E (1993) Kinetics of systemic
and intrahypothalamic IL-6 and tumor
necrosis factor during endotoxin fever
in guinea pigs. Am J Physiol 265:R653–
658
20. LeMay LG, Vander AJ, Kluger MJ
(1990) Role of interleukin 6 in fever in
rats. Am J Physiol 258:R798–803
21. Zampronio AR, Souza GE, Silva CA,
Cunha FQ, Ferreira SH (1994) Inter-
leukin-8 induces fever by a prostaglan-
din-independent mechanism. Am J
Physiol 266:R1670–1674
22. Cartmell T, Luheshi GN, Hopkins SJ,
Rothwell NJ, Poole S (2001) Role of
endogenous interleukin-1 receptor an-
tagonist in regulating fever induced by
localised inflammation in the rat. J
Physiol (Lond) 531:171–180
23. Gabay C, Smith MF, Eidlen D, Arend
WP (1997) Interleukin 1 receptor an-
tagonist (IL-1Ra) is an acute-phase
protein. J Clin Invest 99:2930–2940
24. International Agranulocytosis and
Aplastic Anemia Study (1986) Risks of
agranulocytosis and aplastic anemia. A
first report of their relation to drug use
with special reference to analgesics.
JAMA 256:1749–1757
25. Hargis JB, La Russa VF, Redmond J,
Kessler SW, Wright DG (1989)
Agranulocytosis associated with “Mex-
ican aspirin” (dipyrone): evidence for
an autoimmune mechanism affecting
multipotential hematopoietic progeni-
tors. Am J Hematol 31:213–215
In conclusion, considering the lack of superiority in
decreasing temperature compared to other treatments, the
adverse effects on hemodynamics and the association of
metamizol with the rare but life-threatening agranulocy-
tosis [24, 25] the use of metamizol as a standard
antipyretic treatment should be discouraged, especially
in hemodynamically unstable patients. Indeed, the bene-
ficial effects on metabolism are of minor clinical
relevance and do not justify its administration. Equally
efficient antipyretic treatments such as propacetamol and
external cooling should be preferred. However, special
consideration should be given to patients who are unlikely
to tolerate the increased metabolic demand that may
accompany external cooling, despite adequate sedation.
Uncertainty remains as to whether fever in itself, as
distinct from its cause, is beneficial or harmful, and what
circumstances warrant antipyretic therapy.
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